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Cytochrome P450-dependent arachidonic acid metabolism in human
kidney. Cytochrome P450-dependent arachidonic acid metabolism in
human kidney cortex from several postmortem subjects has been
characterized. Using HPLC and GC/MS, four cytochrome P450-arachi-
donic acid metabolites were tentatively but not unequivocally identified
as epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid
(DHT) and 19- and 20-hydroxyeicosatetraenoic acids, suggesting the
involvement of two major cytochrome P450 enzymes, epoxygenase and
w/w-l hydroxylases. This pattern of metabolism was similar to that
found in rabbit and rat kidneys. The formation of these metabolites was
dependent on the presence of NADPH and inhibited by IgG of
NADPH-cytochrome P450 (c) reductase. Immunologic studies of renal
cytochrome P450 epoxygenase demonstrated that antibodies prepared
against human-purified hepatic cytochrorne P450 epoxygenase recog-
nized renal enzyme protein and inhibited the enzyme activity by 92%.
In contrast, control immunoglobulin did not inhibit renal cytochrome
P450 epoxygenase. Antibody inhibition of renal cytochrome P450
epoxygenase demonstrated a degree of conservation of both enzyme
proteins between liver and kidney. Antibodies against lauric acid who-I
hydroxylases (P450w) inhibited the formation of ailw- I hydroxylase
products, 19- and 20-HETEs. Identical qualitative patterns of arachi-
donic acid metabolites were observed in all cortical microsomes stud-
ied. Interindividual variations were observed in the cytochrome P450-
dependent arachidonic acid metabolism, and the activities ranged from
0.031 to 5.027 nmol arachidonic acid converted/mg protein/30 mm,
which is about a 150-fold difference. However, when the specific
activities for total cytochrome P450-dependent arachidonic acid metab-
olism were calculated, two separate groups could be distinguished, high
and low metabolizers of arachidonic acid. The range of the low
metabolizer of arachidonic acid by cytochrome P450 was 0.15 to 0.23
pmol arachidonic acid convertedipmol P450/mm, as compared to the
range of the high metabolizer which was 1.38 to 1.93 pmol arachidonic
acid converted/pmol P450/mm. The interindividual variation observed
with respect to arachidonic acid metabolism was also observed in other
cytochrome P450 monooxygenase systems studied, aryl hydrocarbon
hydroxylase and 7-ethoxyresorufin-O-deethylase. Arachidonate metab-
olites derived by cytochrome P450 have been shown to possess a wide
range of biological activities; these include stimulation of peptide
hormone release, inhibition and stimulation of NaKtATPase, va-
soreactivity and mobilization of Ca. We suggest that the interindi-
vidual variations observed in cytochrome P450-dependent arachidonic
acid metabolism may play a role in the susceptibility of certain
individuals to develop clinical disorders such as essential hypertension.
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The cytochrome P450-dependent monooxygenases represent
the third pathway by which arachidonic acid (AA) can be
metabolized. In the presence of NADPH and molecular oxygen
[1], the cytochrome P450 system oxidized AA by three types of
reactions: 1) allylic oxidation leading to the formation of mono-
hydroxyeicosatetranoic acids (HETEs); 2) olefin epoxidation
leading to the formation of the four regioisomeric epoxyeicosa-
trienoic acids (EETs), which can undergo hydrolysis by ep-
oxide hydrolase to form the corresponding diol metabolites
(DHTs); 3) oxidation at wand co-i positions to form the 20- and
19-HETEs, respectively [2—4]. The highest concentration of
cytochrome P450 isozymes in mammalian tissues is found in
liver. However, several extrahepatic tissues contain significant
levels of cytochrome P450; among them the kidney displays the
highest concentration [5—7]. Cytochrome P450-dependent me-
tabolism of endogenous substrates such as steroids, fatty acids,
including AA, and prostaglandins in renal tissues may contrib-
ute to kidney function. Cortical and outer medullary mi-
crosomes, isolated proximal tubule cells and isolated cells from
the thick ascending limb of Henle's loop from rabbit kidney
have been shown to metabollize AA by cytochrome P450
enzymes [8]. The cytochrome P450-dependent metabolism of
AA in renal preparations from rabbit and rat kidneys includes
formation of EETs and their hydrolytic metabolites DHTs, and
the co/co-i hydroxylated compounds — 19-HETE and 20-HETE
[9]. Some of these metabolites are biologically active. The
5,6-EET is a vasodilator [10] and an inhibitor of ion transport in
the collecting tubules of rabbit kidney [11]. 11, 12-EET and its
hydrolytic metabolite 11, 12-DHT inhibit AVP-stimulated water
transport and adenylate cyclase in toad bladder [12]. The
ll,12-DHT is a NatKATPase inhibitor [13] and the 19(S)-
HETE is a Na-K-ATPase stimulator [14]. Furthermore, the
20-HETE produced by the kidney is a potent vasoconstrictor
[15]. These biological properties implicate these metabolites in
regulation of various renal functions.
Cytochrome P450 exists in multiple forms which participate
in detoxification of various drugs. The different isozymes of
cytochrome P450 are characterized by their substrate and
product positional specificities and stereoselectivities. Their
qualitative and quantitative proportions in a given tissue vary
largely as a function of various physiological, pharmacological
and pathological conditions [16]. Polymorphism in the oxidative
metabolism of various drugs is a well known phenomenon in
humans [17, 18]. Environment, diet, age, disease and, most
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importantly, genetic factors contribute to this polymorphism.
The metabolism of AA via cytochrome P450 in humans may be
similarly polymorphic [19, 20]. There is no information avail-
able on cytochrome P450-dependent AA metabolism in human
kidney.
The aims of this study were: I) to characterize the cy-
tochrome P450-dependent AA metabolism in human kidney
using antibodies against cytochrome P450 AA epoxygenase and
co/w- 1 hydroxylase in human renal microsomal preparation and
compare it to other species such as rat and rabbit; 2) to
determine the quantitative or qualitative interindividual varia-
tions in cortical cytochrome P450 AA metabolites; 3) to deter-
mine whether the interindividual variation seen with AA also
exists in other monooxygenases in human kidney.
Methods
Reagents
f3-nicotinamide adenine dinucleotide phosphate (NADP),
glucose-6-phosphate, bovine serum albumin, protein markers
for molecular weight determination, phenylmethyl-sulfonyl
flouride (PMSF), 7-ethoxyresorufin, benzo(a)pyrene and cholic
acid were purchases from Sigma Chemical Co. (St. Louis,
Missouri, USA). Glucose 6-phosphate dehydrogenase was pur-
chased from Boehringer Mannheim Biochemicals (Indianapolis,
Indiana, USA). DEAE-cellulose (DE52) was obtained from
Whatman (Clifton, New Jersey, USA). All other chemicals, of
highest quality, were obtained either from Sigma or Fisher
Scientific (Springfield, New Jersey, USA). [l-' CI AA (56.1
mCilmmol) was obtained from Amersham Co. (Arlington
Heights, Illinois, USA).
Radioactive standards of EETs and DHTs were prepared by
non-selective epoxidation of AA with m-chloroperoxybenzoic
acid as described by Chung and Scott [211. The epoxide mixture
was separated by normal-phase HPLC on a uPorasil column
(3.9 mm x 30 cm; Waters Associates, Milford, Massachusetts,
USA) with a solvent composed of hexane/propanol/acetic acid
(955:5:1, by volume) at a flow rate of 3 mI/mm. The structures
of the epoxides were determined by gas chromatography-mass
spectroscopy analysis of the methylesters and methylesters
after hydrogenation. The corresponding DHTs were obtained
by acidic aqueous hydrolysis [221.
Preparation of human cortical microsomes
Human kidneys were obtained from the Department of Lab-
oratories and Research at Westchester County Medical Center
(Valhalla, New York, USA). The kidneys from six males from
22 to 42 years old were obtained within 5 to 12 hours after death
(five car accidents and one cerebral hemorrhage). The renal
cortex was separated, placed in ice-cold 0.15 M KCI and
homogenized (4 ml/g wet wt) in 10 mrs Tris buffer, pH 7.5,
containing 0.25 M sucrose. The tissue homogenates were cen-
trifuged at 27,000 g for 20 minutes at 4°C. The supernatant was
centrifuged at 105,000 g for one hour at 4°C and the resulting
microsomal pellet was resuspended in 0.1 M potassium phos-
phate buffer, pH 7.6, and used for determination of cytochrome
P450 content and monooxygenase activities such as: aryl hy-
drocarbon hydroxylase, 7-ethoxyresorufin-O-deethylase, AA
epoxygenase and oIw- 1 arachidonate hydroxylases. Protein
concentration was determined by the method of Lowry Ct a!
[23] with bovine serum albumin (Fraction V) as a standard.
Cytochrome P450 content and activities
Cytochrome P450 content was measured from the reduced
carbon monoxide difference spectrum using sodium dithionite
as the reducing agent [24]. The absorbance difference between
450 and 490 was used to calculate the cytochrome P450 content,
a molar absorption coefficient of 91 mM' cm' being used.
Aryl hydrocarbon hydroxylase activity was determined, us-
ing benzo(a)pyrene as the substrate following the method of
Nebert and Gelboin [25] as modified in our laboratory [26]. The
standard curve was obtained with various dilutions of 3-hy-
droxy-benzo(a)pyrene (provided by Dr. A. Fiala, American
Health Foundation, Valhalla, New York, USA). 7-Ethoxyre-
sorufin-O-deethylase was measured by the direct fluorometric
procedure as described by Burke and Mayer [27], and modified
by Johnson, Schwab and Muller-Eberhard [281. The reaction
was initiated with 1 mol NADPH and allowed to continue for
10 minutes. The formation of hydroxyresorufin was monitored
using a Perkin Elmer fluorometer (Norwalk, Connecticut, USA)
with an excitation wavelength of 530 nm and emission wave-
length of 586 nm.
Arachidonic acid metabolism
Microsomal suspensions (I mg protein) were preincubated
with indomethacin (10 /LM) for 10 mm and further incubated
with [l-' C]-AA (0.4 tCi, 7 j.M) with or without NADPH (1
mM), or SKF-525A (100 jiM) or both 30 minutes at 37°C. The
reaction was terminated by acidification with citric acid to pH
4.5 to 5.0 and extracted twice with two volumes of ethyl
acetate. The extraction efficiency was 70 to 75%. The final
extracts were evaporated to dryness under N2 and resuspended
in 100 jil of methanol. AA metabolites were separated by high
pressure liquid chromatography (HPLC). Reverse-phase HPLC
was performed on a C18 Bondapack column (Z module; Waters)
with a linear gradient from acetonitrile/water/acetic acid (50:
50:1, by vol) to acetonitrile:acetic acid (100:1, vollvol) at a flow
rate of 1 mI/mm for 40 minutes. Radioactivity was monitored by
a flow detector (Radiomatic Instruments and Chemicals,
Tampa, Florida, USA). In addition, fractions of 0.5 ml each
were collected and aliquots from each fraction were taken for
liquid scintillation counting. The recovery efficiency of the
separation procedure was 80 to 85%.
Gas chromatography/mass spectrometry analysis (GC/MS)
Radioactive peaks eluted from the HPLC were extracted
twice with ethyl acetate and the residue was evaporated under
nitrogen. The methylester derivative was prepared by adding an
ethereal solution of diazomethane for 10 minutes at room
temperature. The trimethylsilyl derivative was then prepared
by incubating the extract with 200 ji! of bis (trimethylsilyl)
trimethylfluoroacetamide for one hour at 60°C. GC/MS analysis
was performed on HP model 5985A (Hewlett Packard, Palo
Alto, California, USA), equipped with HP models 7906 and
7920 data systems. The GC column was 1% SE-30 column
(Supelco, Bellefonte, Pennsylvania, USA) operated between
180 to 270°C at a rate of 8°C/mm. The ion source temperature
was 200°C and the electron energy was 70 eV.
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Preparation of antibodies to human liver cytochrome P450
AA epoxy genase
The procedure used for the purification of human liver
cytochrome P450 AA epoxygenase was as previously described
by our laboratory [29]. Control antibody was purified in an
identical manner using sera from nonimmunized rabbits. The
final protein concentration of the antibody preparation was 6
mg/ml.
Immunotitration of human kidney cytochrome P450
epoxy genase
Immunotitration of cytochrome P450 epoxygenase was sim-
ilar to that described previously [30]. Briefly, serial dilution of
preimmune and immune purified rabbit sera were prepared in
0.9% sodium chloride containing 0.02 M potassium phosphate
buffer, pH 8.0, in a final volume of 400 l. Each tube then
received 400 l of enzyme containing preparation to be titrated.
The mixture was incubated for 25 minutes at 25°C with various
amounts of rabbit anti-human IgG of cytochrome P450 epoxy-
genase. After centrifugation at 15,000 x g for 20 minutes, the
supernatant fractions were assayed for AA metabolism as
described above. In the control, the enzyme activity did not
change significantly during the pre-incubation period, and the
pre-immune serum did not precipitate detectable quantities of
cytochrome P450 epoxygenase. We found that the level of
inhibition of cytochrome P450 epoxygenase was achieved when
the ratio of antibodies to microsomal protein was 1:3.
Results
Arachidonic acid metabolism by renal microsomes via
cytochrome P450-dependent monooxygenase
Metabolites of AA formed by cytochrome P450-dependent
enzyme(s) were defined as those metabolites whose formation
was absolutely dependent on NADPH addition, inhibited by
SKF-525A, an inhibitor of cytochrome P450-dependent en-
zymes via a type-I binding mechanism [31], or inhibited by
antibodies to cytochrome P450 (c) reductase [30], the essential
component of the electron transport cytochrome P450 mono-
oxygenase system. The various metabolites were separated by
HPLC. Table 1 shows the retention times of various synthetic
standards of cytochrome P450-AA metabolites on reverse
phase HPLC. In the absence of NADPH, the conversion of
14C..AA was very low (3 to 5% of total radioactivity) and
accounted for mainly by cyclooxygenase metabolites. In the
presence of NADPH, AA was converted into cytochrome
P450-derived metabolites by all human renal microsomal prep-
arations studied. The formation of these metabolites was inhib-
ited by SKF-525A (100 MM), an inhibitor of cytochrome P450-
dependent enzyme, but was not affected by indomethacin (10
t.M) a cyclooxygenase inhibitor indicating that they are derived
by the cytochrome P450 pathway (data not shown). Figures lA
and lB represent HPLC separation of AA metabolites formed
by cortical microsomes of subjects 4 and 5, respectively, in the
presence of NADPH. Three major radioactive peaks were
separated: peaks I, II and III. Peak I was eluted between 14 and
16 minutes and corresponded to the DHT metabolites (Table I).
Peak II eluted at 17 minutes and comigrated with 19- and
20-HETE standards (Table 1), whereas peak III eluted at 23.8
minutes, a similar retention time to 11, 12-EET. We obtained
Compound
Retention time
mm
14,15 DHT 13.2
11,12 DHT 14.5
8,9 DHT 15.0
5,6DHT 15.7
20-HETE 17.9
19-HETE 18.2
15-HETE 18.7
12-HETE 19.8
5-HETE 21.3
14,15 EET 23.0
11,12EET 23.9
8,9 EET 24.3
5,6 EET 25.2
Arachidonic acid 31.0
Separation of the various metabolites was performed by reverse
phase HPLC using C18-Bondapak column as described under Meth-
ods.
relatively large amounts of peaks I, II and III (2 to 5 g) and
determined the structure of metabolites by gas chromatogra-
phy/mass spectometry (GC/MS).
The mass spectra of the methylester trimethylsilyl derivative
of peak II showed the presence of two metabolites, ha and II b,
with a c value of 20.9 and 21.3, respectively. Ions in the upper
mass range were noted at mlz 406(M), 391(M-15), 375(M-
31), and 359(M-15-31) for both compounds. After hydrogena-
tion, a major ion at mlz 117 [base peak fragment of
CH3CHOSi(CH3)3] was noted for compound ha, suggesting the
structure of 19-HETE. The hydrogenated methylester trimeth-
ylsilyl derivative of compound lIb showed a major ion at m/z
103 [fragment of CH3OSi(CH3)3}, suggesting the structure of
20-HETE. The structure of these metabolites is similar to that
described in rabbit and rat renal cortical microsomes [2, 3, 9].
The major compound in peak III had a c value of the 20.2 and
showed characteristic ions of an epoxide metabolite with frag-
ments at m/z 334(M), 316(M-18), and 303(M-31). The mass
spectra of the hydrogenated methylester derivative of this
compound showed fragments at m/z 340(M), 322(M-l8),
and 309(M-3l) and ions at mlz 155 [M-(CH2)9CO2CH2] and
227[M-( l55-C2H20)], suggesting the structure of 11,12-
EET.The same mass spectra was obtained for the hydrogenate
11,1 2-EET standard when applied in El mode. However, due to
limited amounts, we cannot exclude the possibility that other
EETs were formed. The GC/MS analysis of the derivatized
peak I showed the presence of two compounds, the major one
(70%) had fragments at m/z 496(M), 48l(M-15), 4M(M-9O),
315, 295 and 213, suggesting the structure of 11 ,12-DHT.
The comigration of these metabolites on an HPLC with
standard compounds and the GC/MS data are consistent with
the structure of these metabolites and clearly reveal the pres-
ence of at least two types of oxidative pathways represented by
two or more isozymes. The first type was catalyzed by cy-
tochrome P450 epoxygenase activity which is represented by
the formation of epoxides, mainly 11, 12-EET (peak III) and
their hydrolytic metabolites DHT, mainly 11, l2-DHT (peak I).
The second type of oxidative pathway is catalyzed by os'cu- 1
hydroxylases which are represented by the formation of 19-
HETE and 20-HETE (peak II).
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Fig. I. Reverse-phase HPLC of arachidonic acid metabolites formed by renal cortex ,nicroso,nes of subject 4 (A) and subject 5 (B). Microsomes
(I mg protein) were incubated with '4C-AA (0.4 sCi, 7 ) in the presence of NADPH for 30 minutes at 37°C. Arachidonate metabolites were
extracted and separated by reverse-phase HPLC as described in Methods. (PGs - prostaglandins; I - DHT; II - 19-HETE, 20-HETE; LII - EETs;
AA - arachidonic acid).
To distinguish between the oxidative pathways of AA by
cytochrome P450, we carried out the following series of exper-
iments: human cortical microsomes were incubated with anti-
bodies prepared against the purified human liver cytochrome
P450 epoxygenase. The formation of cytochrome P450 AA
metabolites (Fig. 2A) which was dependent on NADPH addi-
tion (Fig. 2C), was inhibited by IgG to human liver cytochrome
P450 AA epoxygenase (Fig. 2B). As seen in Figure 2B, forma-
tion of peak III (mainly 11, 12-EET) was inhibited by 90%,
whereas the formation of peaks I (mainly 11 ,12-DHT) and II
(19- and 20-HETEs) was inhibited by 50% and 40%, respec-
tively. Peak II, which is a product of o/w-1 hydroxylase, was
inhibited by 40% when microsomes were incubated with IgG of
lauric acid w/o-l hydroxylase (P450). The formation of AA
metabolites via w/w 1 hydroxylase as well as via AA epoxyge-
nase was prevented by antibodies to cytochrome P450 (c)
reductase, an integral component of all cytochrome P450 mono-
oxygenase systems, whereas the pre-immune IgG had no effect
(data not shown).
A summary of the P450 contents and specific activities of the
two AA oxidative pathways as well as other cytochrome P450
monooxygenases present in renal microsomes from six subjects
is represented on Table 2. Note that large variations (40- to
100-fold) exist between individual subjects for the activities of
coloj-1 hydroxylase and epoxygenase, respectively. Further-
more, determinations of specific activities revealed a group of
subjects with low specific activity, 0.15 to 0.23 pmol AA/
minlpmol cytochrome P450 (subjects number 1,2,6) and a group
with high specific activity, 1.38 to 1.93 pmol AA/min/pmol
cytochrome P450 (subjects number 3,4,5).
The cytochrome P450 content and its dependent monooxy-
genase activities, aryl hydrocarbon hydroxylase and 7-ethoxy-
resorufin-O-deethylase, were also measured in renal cortical
microsomes. As seen in Table 2, cytochrome P450 was present
in spectrally detectable amounts in human cortical microsomes,
although the basal levels varied dramatically in individuals
examined. These variations were also observed in the activities
of the cytochrome P450 monooxygenase system. Renal micro-
somes from subject 3 possessed aryl hydrocarbon hydroxylase
activities of 998 as compared to 9.6 pmol 3-OH benzo(a)pyrene/
mg/mm in subject 6. Similar observations in benzo(a)pyrene
metabolism can be seen between other subjects with a variation
of a 25- to 100-fold difference. The level of aryl hydrocarbon
hydroxylase activities did not follow the amount of cytochrome
P450 level. Thus, although renal cortex from subject 6 showed
the lowest aryl hydrocarbon hydroxylase activity, its cy-
tochrome P450 content was not the lowest level observed
(Table 2).
The activity of 7-ethoxyresorufin-O-deethylase was also com-
pared among the six subjects. We observed a similar individual
variation in the levels of 7-ethoxyresorufin-O-deethylase; the
largest differences were observed between subjects number 3
and 5.
Discussion
In this paper, we demonstrated that human kidney metabo-
lized AA by two types of oxidative pathways, epoxygenase and
wko-1 hydroxylase. Formation of AA metabolites by human
kidney cytochrome P450 was dependent on the presence of
NADPH and inhibited by antibodies against cytochrome P450
(c) reductase. These metabolites resembled those described in
rabbit and rat kidney [9, 32]. In this investigation, we have used
antibodies against human liver cytochrome P450 AA epoxyge-
nase to characterize human kidney cytochrome P450 epoxyge-
nase. Antibodies raised against human liver cytochrome P450
AA epoxygenase inhibited the formation mainly of peak III
(EETs) of renal cytochrome P450 metabolism of AA.
Although we observed identical qualitative patterns of AA
metabolites by human cortical cytochrome P450 from different
subjects, there were large quantitative differences in total
A AA I B
II
p I I I I I I I I I I I
35 30 25 20 15 10 5 0 35 30 25 20 15 10 5 0
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Table 2. Levels ofcytochrome P450 and activities of AA-epoxygenase, AA-hydroxylases, aryl hydrocarbon hydroxylase,
7-ethoxyresorufin-O-deethyiase in human kidney microsomes
aj/w-l
Subject
P450 content
pmo!/mg
AA-epoxygenase Hydroxylase
AHH 7-ERpmol/mg/min
1 28 1.9 2.4 21.2 4.0
2 33 1.0 3.9 67.5 9.1
3 184 167,5 86.2 998.0 10.5
4 99 135.7 55.8 351.0 3.0
5 33 27.0 20.6 27.5 2.2
6 52 4.2 7.6 9.6 ND
Renal cortical microsomes from six individuals were prepared and the cytochrome P450 content, AA-epoxygenase (formation of EET + DHT,
peaks III and I), AA-hydroxylase (formation of peak II), aryl hydrocarbon hydroxylase and 7-ethoxyresorufin-O-deethylase were measured as
described in Methods. The results are the mean of two determinants.
7
6
5
4
3
2
1
0
10
9
8
7
6
5
4
3
2
1
0
LL
c
cytochrome P450 AA metabolism. Thus, there are individuals
in which the specific activity of the cytochrome P450-dependent
AA metabolizing isozymes is higher than others by a factor of
100. The presence of these isozymes may contribute to the
capacity of the individual to metabolize AA. As seen in Table 2
there are low and high metabolizers of AA to the epoxides and
w/u 1 hydroxylated compounds. Part of the quantitative differ-
ences may be due to variation in postmortem time. Indeed, in
experiments with rat and rabbits in which we measured renal
cytochrome P450 content and its activities including AA me-
tabolism at different postmortem times (5 to 12 hr), we observed
gradual reduction up to 50% by 12 hours. Thus, a one- to
twofold difference may account for autolysis followed by dif-
ferent postmortem time. However, a 50- to 100-fold difference
observed in cytochrome P450 AA metabolism is a reflection of
intraindividual variation previously reported for other cy-
tochrome P450 enzymes in human liver [17—19].
In addition, we recently obtained biopsies of human kidney
cortex from patients with hypernephroma. The tissues were
placed in liquid nitrogen immediately upon surgery. The P450
content and its activities including AA metabolism in microso-
mal preparations were measured. The values obtained in nor-
mal kidney cortex biopsies for these activities were in similar
ranges to that in the postmortem tissues, that is, between 8.0
and 104.4 pmol AA/mg/min.
Previous work from our laboratory, as well as others, has
shown that epoxides derived from epoxygenase activity are
potent secretagogues, vasodilators, and inhibitors of ion trans-
port mechanisms [10—13,33]. We also demonstrated that the
formation of 19- and 20-HETE is increased during the develop-
ment of hypertension in spontaneously hypertensive rats, sug-
gesting their involvement in the elevation of blood pressure
[34]. We recently demonstrated the ability of 19(S)HETE to
stimulate Na-K-ATPase at physiological concentrations [14].
This biological property of 19(S)HETE is compatible with the
sodium retention which occurs in the early stage of blood
pressure elevation in the spontaneously hypertensive rats [34].
Furthermore, 20-HETE is a potent vasoconstrictor [15] and
may affect renal vascular resistance and contribute to the
pathogenesis of hypertension. Thus by manipulating Na4-
K4-ATPase activity, dilating and/or constricting vascular
smooth muscles, these metabolites may influence renal function
and contribute to the development of a pathological state such
as hypertension.
It is interesting to note that the kidney of subject 3 came from
a 42-year-old male who had died from cerebral hemorrhage, a
possible manifestation of untreated essential hypertension. This
10
9
8
7
6
5
4
3
2
1
0
1
10 20 30 4050 60 70 S
1 10 20 30 40 50 60 70 80
Fraction number
FIg. 2. Reverse-phase HPLC of arachidonic acid metabolites formed
by human renal cortex microsomes. Microsomes (I mg protein) were
incubated with '4C-AA (0,4&Ci) for 30 minutes at 37°C. (A) control
incubation in the presence of 1mM NADPH; (B) microsomes were
preincubated with anti-human liver cytochrome P450 epoxygenase IgG
(0.3 mg) for 25 minutes at 25°C prior to the addition of NADPH and
'4C-AA; (C) microsomes in the absence of NADPH. The reactions were
terminated by acidification, and AA metabolites were extracted and
separated by reverse-phase HPLC as described in Methods.
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kidney demonstrated the highest activity of both wlw- 1 hydrox-
ylase and epoxygenase. A large number of individuals grouped
for age and sex as well as for normal and hypertensive states
would have to be screened for the level of P450-AA enzymes
before an association between these isozyme activities and
hypertension can be established.
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